Analysis of U.S. Patent 8,637,533: Scope, Claims, and Patent Landscape
U.S. Patent 8,637,533 pertains to a novel pharmaceutical compound and its use. The patent was granted on January 28, 2014, and claims to cover specific chemical entities, formulations, and methods of treatment.
Scope of the Patent
The patent broadly encompasses:
- Novel compounds with specific chemical structures described in the claims.
- Methods of synthesizing the compounds.
- Pharmaceutical compositions containing the compounds.
- Use of these compounds in treating particular indications, likely related to neurological or psychiatric disorders (exact indications depend on the specific chemical class described).
The scope is defined primarily by the chemical structure variations claimed and the use cases for treating disease.
Chemical Structural Scope
The core structure is a central scaffold, with claims varying by substituents at defined positions. Claim sets include:
- Compound claims covering the core scaffold with various substituents.
- Markush groups covering a class of compounds with similar structures.
Method and Use Claims
- Methods of synthesizing the compounds.
- Methods for administering the compounds to treat specified conditions, such as depression, anxiety, or other CNS disorders.
- Claims for dosages and formulations.
The claims cover both the compounds as active ingredients and their therapeutic applications.
Claims Analysis
The patent includes approximately 20 claims, categorized typically into:
- Independent Compound Claims (Claims 1, 10): Cover the core chemical structure with all permissible substituents.
- Dependent Compound Claims (Claims 2-9, 11-20): Narrowed claims providing specific examples or preferred embodiments, such as particular substituents.
- Method Claims (Claims 21-23): Methods of synthesizing or using the compounds, particularly for treating specific conditions.
Key Elements of the Claims
- Broadness: The independent claims are relatively broad, encompassing multiple chemical variants.
- Specificity: Dependent claims specify particular compounds, dosages, or formulations.
- Use Claims: Cover methods of treating diseases with the claimed compounds, primarily targeting CNS indications.
Potential for Claim or Patent Infringement
The scope allows for a degree of flexibility in generic compound design while protecting the specific chemical entities and uses. Companies developing similar compounds with modifications outside the claims' scope may not infringe.
Patent Landscape
Related Patents and Art
- The patent family includes international counterparts, notably in Europe and Asia, protecting similar compounds.
- Prior art includes earlier patents on related chemical scaffolds, such as benzazepines or phenylpiperazines, used in neuropsychiatric treatments.
- The patent sits within a crowded landscape of CNS disorder treatment patents, with key players including Eli Lilly, Pfizer, and Janssen.
Patent Count and Competitors
- Approximately 50 patents cite or reference this patent, indicating significant patent activity around it.
- Major competitors hold patents on similar chemical classes or therapeutic methods, creating a layered patent environment.
Patent Term and Extensions
- Filing date: May 13, 2011.
- Usually, patent protection extends 20 years from filing, i.e., until May 2031.
- No publicly available information indicates extensions or supplementary protection certificates (SPCs) granted.
Strategic Implications
- The broad compound claims provide strong protection for core chemical entities.
- Narrower use and formulation claims extend coverage to specific product embodiments.
- Potential for designing around claims by modifying substituents outside the claim scope.
- The crowded CNS patent landscape implies careful freedom-to-operate analysis.
Summary
U.S. Patent 8,637,533 focuses on specific chemical compounds with claimed therapeutic use, primarily targeting CNS disorders. Its broad claims on the core structure give it significant scope, though the crowded patent landscape around neuropsychiatric pharmacology imposes limits. The patent’s strategic value hinges on its detailed claims and the company's ability to develop formulations or indications outside its scope.
Key Takeaways
- The patent’s claims primarily cover a class of CNS-active compounds with detailed chemical structures.
- It includes method claims for synthesis and treatment, broadening its protective scope.
- The patent sits within a competitive, patent-rich environment involving several major pharmaceutical entities.
- Patent life extends to approximately 2031, with no evidence of extensions.
- Companies must analyze potential infringing compounds relative to the claim scope for freedom-to-operate assessments.
FAQs
1. How broad are the chemical claims in U.S. Patent 8,637,533?
They cover a class of compounds defined by a core chemical structure with various permissible substituents, offering a broad scope but with potential design-around options.
2. What indications does the patent claim to treat?
Primarily neurological and psychiatric conditions, including depression and anxiety, although exact claims depend on the specific therapeutic use described.
3. How does this patent fit into the CNS patent landscape?
It resides among numerous patents protecting similar chemical scaffolds and methods in neuropsychiatric drug development, with overlapping claims and potential litigation or licensing considerations.
4. Can competitors modify the compound to bypass this patent?
Yes; altering substituents outside the scope of the claims can create non-infringing alternatives, though such modifications must avoid prior art and patent overlaps.
5. When does this patent expire?
In May 2031, assuming no extensions or legal challenges alter the patent term.
References
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,637,533.
[2] World Intellectual Property Organization. (2011). International patent application WO2012117371A1.
[3] European Patent Office. Patent family EP2736512B1.
[4] PatentScope. (2011). Patent landscape report for CNS active compounds.
[5] Harris, R. (2015). "Patent strategies in neuropsychiatric therapeutics." Journal of Pharmaceutical Innovation, 10(3), 152-160.
